Purple Biotech
PPBTPurple Biotech Ltd. (NASDAQ: PPBT) is an Israel-based clinical-stage biotechnology company focused on developing oncology therapeutics. The company's primary business focus is the discovery and development of treatments designed to counteract tumor immune evasion mechanisms and address drug resistance in cancer. Its pipeline consists of several clinical-stage assets targeting specific pathways involved in these processes. The company's lead candidate, CM24, is a monoclonal antibody directed against CEACAM1, an immune checkpoint protein implicated in tumor progression and immune suppression. CM24 is being evaluated in combination with nivolumab (Opdivo®) in a Phase 2 study for non-small cell lung cancer and pancreatic ductal adenocarcinoma. A second clinical asset, NT219, is a dual inhibitor targeting IRS1/2 and STAT3, key signaling nodes involved in resistance to multiple anti-cancer therapies. NT219 is in Phase 1/2 studies for recurrent and metastatic solid tumors, including head and neck cancer. As a publicly traded entity, Purple Biotech advances its research and development programs from its operations in Israel. The company's strategic approach centers on advancing its clinical pipeline through targeted clinical trials to generate data on the efficacy and safety of its therapeutic candidates in specific oncology indications.
PPBT · Stock Price
Historical price data
About
Purple Biotech Ltd. (NASDAQ: PPBT) is an Israel-based clinical-stage biotechnology company focused on developing oncology therapeutics. The company's primary business focus is the discovery and development of treatments designed to counteract tumor immune evasion mechanisms and address drug resistance in cancer. Its pipeline consists of several clinical-stage assets targeting specific pathways involved in these processes. The company's lead candidate, CM24, is a monoclonal antibody directed against CEACAM1, an immune checkpoint protein implicated in tumor progression and immune suppression. CM24 is being evaluated in combination with nivolumab (Opdivo®) in a Phase 2 study for non-small cell lung cancer and pancreatic ductal adenocarcinoma. A second clinical asset, NT219, is a dual inhibitor targeting IRS1/2 and STAT3, key signaling nodes involved in resistance to multiple anti-cancer therapies. NT219 is in Phase 1/2 studies for recurrent and metastatic solid tumors, including head and neck cancer. As a publicly traded entity, Purple Biotech advances its research and development programs from its operations in Israel. The company's strategic approach centers on advancing its clinical pipeline through targeted clinical trials to generate data on the efficacy and safety of its therapeutic candidates in specific oncology indications.